|
Biochemically verified continuous abstinence at six months % (n)
|
14% (5)
|
5% (2)
|
0
|
0.245 (patch vs. 16 mg e-cig)a
|
|
- (16 mg vs. 0 mg e-cig)
|
|
0.115 (patch vs. combined e-cig)a
|
|
Relapse rate at six months % (n)
|
71% (25)
|
85% (33)
|
83% (10)
|
0.169 (patch vs. 16 mg e-cig)
|
|
1.000 (16 mg vs. 0 mg e-cig)
|
|
0.149 (patch vs. combined e-cig)
|
|
Mean reduction in CPD from baseline to six months in those that did not quit Mean (SD)
|
5.7 (6.3)
|
9.9 (7)
|
4.7 (3.5)
|
0.035 (patch vs. 16 mg e-cig)
|
|
0.068 (16 mg vs. 0 mg e-cig)
|
|
0.083 (patch vs. combined e-cig
|
|
Percentage reduction in CPD from baseline to six months in those that did not quit Mean (SD)
|
29% (30%)
|
49% (30%)
|
31% (30%)
|
0.025 (patch vs. 16 mg e-cig)
|
|
0.153 (16 mg vs. 0 mg e-cig)
|
|
0.049 (patch vs. combined e-cig)
|
|
Treatment compliance at three months % (n)
|
20% (6)
|
53% (19)
|
46% (5)
|
0.006 (patch vs. 16 mg e-cig)
|
|
0.670 (16 mg vs. 0 mg e-cig)
|
|
0.006 (patch vs. combined e-cig)
|
|
Adverse events
|
17 (in 16 people)
|
22 (in 15 people)
|
5 (in 4 people)
|
-
|
|
Acceptability of intervention at six months
|
|
‘Would recommend to a friend’
% (n)
|
37% (11)
|
83% (30)
|
80% (8)
|
<0.001 (patch vs. 16 mg e-cig)
|
|
1.000a (16 mg vs. 0 mg e-cig)
|
|
<0.001 (patch vs. combined e-cig)
|
|
‘Stopped as didn’t like it’
% (n)
|
41% (12/29)
|
29% (7/24)
|
22% (2/9)
|
0.356 (patch vs. 16 mg e-cig)
|
|
1.000a (16 mg vs. 0 mg e-cig)
|
|
0.242 (patch vs. combined e-cig)
|
